Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of YG1699 in Healthy Chinese Subjects
NCT05089617Phase 1Completed
- Sponsor
- Youngene Therapeutics
- Start
- Jan 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of YG1699 in type 2 diabetes mellitus (T2DM) and type 1 diabetes mellitus (T1D) (3 cohorts), sponsored by Youngene Therapeutics. Primary endpoint: Number of participants with adverse events at 81 Days. Started Jan 2022; status: completed.
02
Drugs
YG1699
03
Conditions
type 2 diabetes mellitus (T2DM)type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05089617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05089617.